PTC Therapeutics Q2 2024 GAAP EPS $(1.29) Misses $(1.19) Estimate, Sales $186.704M Beat $185.319M Estimate
Portfolio Pulse from Benzinga Newsdesk
PTC Therapeutics (NASDAQ:PTCT) reported Q2 2024 GAAP EPS of $(1.29), missing the $(1.19) estimate by 8.4%. However, sales of $186.704M beat the $185.319M estimate by 0.75%, though this is a 12.68% decrease from the same period last year.
August 08, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics reported a Q2 2024 GAAP EPS of $(1.29), missing the $(1.19) estimate by 8.4%. Sales of $186.704M beat the $185.319M estimate by 0.75%, but this is a 12.68% decrease from the same period last year.
The miss on EPS by 8.4% is likely to have a negative impact on the stock price in the short term, despite the slight beat on sales. The 12.68% YoY decrease in sales further adds to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100